Kymera Therapeutics (NASDAQ:KYMR) Trading 6.4% Higher – Time to Buy?

Kymera Therapeutics, Inc. (NASDAQ:KYMR)’s stock price traded up 6.4% during mid-day trading on Tuesday . The company traded as high as $39.83 and last traded at $39.60. 96,796 shares traded hands during mid-day trading, a decline of 77% from the average session volume of 412,401 shares. The stock had previously closed at $37.22.

Analyst Ratings Changes

Several research analysts have recently weighed in on KYMR shares. Truist Financial reiterated a “buy” rating and set a $53.00 price objective (down from $54.00) on shares of Kymera Therapeutics in a report on Friday, November 1st. BTIG Research started coverage on shares of Kymera Therapeutics in a report on Tuesday, December 10th. They set a “buy” rating and a $60.00 price objective on the stock. Guggenheim increased their price objective on shares of Kymera Therapeutics from $45.00 to $52.00 and gave the stock a “buy” rating in a report on Friday, November 1st. Stephens started coverage on shares of Kymera Therapeutics in a report on Monday, November 18th. They set an “overweight” rating and a $65.00 price objective on the stock. Finally, BMO Capital Markets started coverage on shares of Kymera Therapeutics in a report on Friday, December 6th. They set a “market perform” rating and a $55.00 price objective on the stock. Three investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $55.38.

Kymera Therapeutics Price Performance

The company’s 50-day simple moving average is $43.45 and its 200-day simple moving average is $44.25. The company has a market cap of $2.62 billion, a price-to-earnings ratio of -17.28 and a beta of 2.19.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings data on Thursday, October 31st. The company reported ($0.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.83) by $0.01. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The company had revenue of $3.74 million during the quarter, compared to the consensus estimate of $10.34 million. During the same quarter last year, the company earned ($0.90) earnings per share. Kymera Therapeutics’s revenue for the quarter was down 20.9% on a year-over-year basis. Equities analysts predict that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Insider Transactions at Kymera Therapeutics

In other news, insider Ellen Chiniara sold 3,129 shares of the firm’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $41.75, for a total transaction of $130,635.75. Following the completion of the sale, the insider now owns 54,826 shares of the company’s stock, valued at approximately $2,288,985.50. This trade represents a 5.40 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 15.82% of the company’s stock.

Institutional Trading of Kymera Therapeutics

A number of hedge funds have recently made changes to their positions in KYMR. Values First Advisors Inc. acquired a new stake in shares of Kymera Therapeutics during the third quarter worth approximately $61,000. Quarry LP bought a new position in Kymera Therapeutics during the third quarter worth $95,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in Kymera Therapeutics by 27.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company’s stock worth $114,000 after purchasing an additional 504 shares during the last quarter. Public Employees Retirement Association of Colorado bought a new position in Kymera Therapeutics during the second quarter worth $139,000. Finally, XTX Topco Ltd bought a new position in Kymera Therapeutics during the second quarter worth $201,000.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.